Evotec Advances Neuroscience Partnership with Bristol Myers Squibb

Evotec SE has announced significant progress in its strategic partnership with Bristol Myers Squibb. This advancement bolsters the joint neuroscience pipeline and involves a payment of US$25 million to support further research.

The collaboration, initiated in December 2016, aims to discover treatments for neurodegenerative diseases. The progress leverages Evotec’s PanOmics platform and patient-derived disease models. This platform is one of the largest in the industry.

The partnership has already produced a promising pipeline. A key achievement was the in-licensing of EVT8683 by Bristol Myers Squibb in 2021. Earlier this year, the partnership was extended for an additional 8 years.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, highlighted the productive nature of the partnership and expressed excitement about advancing yet another program towards clinical development in 2026.